ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Congress investigates how pharma middlemen affect drug prices

House Republicans are investigating pharmacy-benefit managers, middlemen in drug price negotiations, over whether they create unnecessary costs for prescription drugs.

House Republicans have launched an investigation into the companies that manage drug benefits, dialing up the scrutiny of the middlemen who play an important role in how much medicines cost.

The House Oversight and Accountability Committee said Wednesday that it has sent letters to CVS Health Corp.’s CVS Caremark, Cigna Group’s Express Scripts and UnitedHealth Group Inc.’s OptumRx – the largest pharmacy-benefit managers (PBM) – seeking documents about the drug-price rebates they negotiate and fees they charge.

The committee also said it has sent requests to the Centers for Medicare and Medicaid Services and other federal agencies asking for their contracts with the PBMs.

"Greater transparency in the PBM industry is vital to determine the impact that their tactics are having on patients, the pharmaceutical market and health care programs administered by the federal government," said Rep. James Comer, R-Ky., who chairs the oversight committee.

SEN. RICK SCOTT DOUBLES DOWN ON PLAN TO ‘FIX’ SOCIAL SECURITY, MEDICARE AND 'LIVE WITHIN OUR MEANS'

The committee is especially interested in how PBMs affect drug costs overall and the prices patients pay at the pharmacy counter and in their health-insurance premiums in particular, according to a committee staffer.

A representative for PBMs pointed to a 2019 Government Accountability Office report that found the benefits managers won billions in savings for certain Medicare plans and kept less than 1% of the rebates they negotiated in 2016.

COMER BLASTS BIDEN, SCHUMER FOR TRYING TO 'SCARE SENIORS' BY SAYING GOP WANTS TO CUT SOCIAL SECURITY, MEDICARE

"Pharmacy-benefit companies have a proven track record of reducing prescription-drug costs," said JC Scott, president of the Pharmaceutical Care Management Association, a trade association that represents PBMs. "In the Medicare prescription-drug program, the work pharmacy-benefit companies do to push big drug companies for cost concessions is the primary force in keeping monthly premiums affordable."

The requests come after the Federal Trade Commission launched an investigation of PBM practices and several state governments began probes. The problem of high drug prices is a popular concern, and a rare source of agreement among Republican and Democratic lawmakers as well as a potential area for joint legislation.

PBMs, which often handle payments for medicines, are supposed to play a crucial role in keeping a lid on costs. Health insurers and employers hire the firms to negotiate rebates. PBMs oversee other cost-control efforts, including the paperwork required for pricey treatments.

The companies say their work saves health insurers, employers and patients. But they have drawn criticism, especially from pharmaceutical companies, that their push for discounts and other business practices actually has the opposite effect of increasing drug prices.

Mr. Comer, the oversight-committee chair, issued a report in December saying the companies drive up health costs.

PBMs have blamed high drug prices on pharmaceutical companies and pointed to manufacturers who allegedly game the patent system to avoid lower-price competition.

CLICK HERE TO GET THE FOX BUSINESS APP

The oversight committee asked for records from the Defense Health Agency and the Office of Personnel Management, along with Medicare parent CMS.

In addition to seeking records about rebates and fees from the PBMs, the committee asked the companies for documents related to their relationships with Zinc Health Services, Ascent Health Solutions and Emisar Pharma Services, three so-called group purchasing organizations that the PBMs formed to help negotiate rebates.

The committee aims to produce a report recommending potential legislation, the committee staffer said. 

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.